Investor Relations
Recent Releases
Jul 23, 2008
MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affairs
Jul 16, 2008
MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
Jul 14, 2008
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Stock Information
| NASD:MAPP
$9.20 |
+ 0.10 |
| Jul 23, 2008 | 4:10 PM ET |
Quotes delayed at least 20 minutes.
Information provided by TurboFeed.
Information provided by TurboFeed.

